Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.
2. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395–405.
3. Sparano JA, Gray RJ, Makower DF, et al. Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. In: Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting. May 31–June 4, 2019; Chicago, Illinois. 2019. Abstract 503.
4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCB). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
5. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B‑33 trial. J Clin Oncol. 2008;26:1965–71.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. An update from the 2019 ASCO Annual Meeting;memo - Magazine of European Medical Oncology;2019-12